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Abstract Popularity of laparoscopic sleeve gastrectomy
(LSG) has been growing gradually. The aim of this study
was to determine changes in metabolic syndrome parameters
as well as insulin, total cholesterol, and LDL cholesterol, and
to describe the influence of body weight loss on co-
morbidities in obese patients after LSG with 1-year follow-
up. The material consists of 130 patients who underwent LSG
(2007–2010)inordertotreatmorbidobesityandwhohadmet
before the surgery at least three criteria necessary for the
diagnosis of metabolic syndrome according to the Interna-
tional Diabetes Federation. The influence of LSG on co-
morbidities was also analyzed. During 1-year follow-up after
LSG, we obtained a statistically significant decrease in BMI
(from 53.18±7.5 kg/m
2 to 31.4±3.75 kg/m
2, p<0.00001)
and a reduction in waist circumference. Twelve months after
the surgery, excess weight loss (EWL) was 59.42±7.21%
and excess body mass index loss (EBL) was 61.03±6.50%.
One year after LSG, the amount of patients with diagnosed
metabolic syndrome decreased in 61 patients (53.08%). After
1 year, none of the patients met five criteria of metabolic
syndrome. According to efficiency in body mass loss
presented by %EWL and %EBL, LSG is gaining approval
as a method of obesity and metabolic syndrome treatment,
although it is a relatively new procedure. LSG is rather an
easy procedure; the time of performance and hospitalization
are shorter which entails normalization in all parameters of
metabolic syndrome and decreases the percentage of obese
patients with metabolic syndrome.
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Introduction
Global epidemic of obesity is one of the major health issues
in the twenty-first century which influence many aspects of
public health, including psychosocial and socio-economic
aspects. According to the latest report of WHO, in 2011 the
amount of people with BMI >30 reaches 0.5 mld which is
10% of the world population. It is worth noting that almost
double increase of percentage of people with morbid
obesity has been observed during last 30 years [1].
Correlations between metabolic changes examined for
decades finally allowed scientists to define metabolic
syndrome—MS (described also as syndrome X, insulin
resistance syndrome, deadly quartet) as a coexistence of
abdominal obesity, hypertension, accelerated level of
glucose, and disorders in lipid management [2–5]. The best
known are definitions of World Health Organization from
1998, definition of American Diabetes Association (the
most frequently applied and with historical background),
and the latest definition of International Diabetes Federa-
tion [6–8]. In Poland, in accordance with AHA–NHLBI
definition, 23% of men and 20% of women meet the criteria
for the diagnosis of metabolic syndrome [9]. The results of
epidemiological tests indicate significant dissemination of
occurrence of metabolic syndrome in USA as well as in
Europe. It is estimated that among adult citizens of
developed countries, 30–35% of middle-aged people meet
the criteria for the diagnosis of metabolic syndrome [10].
The scale of the problem is illustrated by the fact that
patients with diagnosed metabolic syndrome are three times
more likely to collapse for a heart attack or stroke and five
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DOI 10.1007/s11695-011-0530-ytimes more likely to develop type 2 diabetes [11–13]. To
detain or to decrease the rate of rising amount of patients
with metabolic disorders (including obese patients) is now
one of the major medical challenges. Currently, in connec-
tion with the development of bariatric surgery, which
provides long-lasting effects in obesity treatment, it is also
reasonable to search for the methods that would not only
constantly reduce body mass but would also would
normalize lipid management and bring the best therapeutic
results in treatment of type 2 diabetes [14]. The popularity
of laparoscopic sleeve gastrectomy (LSG), a relatively new
bariatric procedure among all surgical methods of treating
obesity, has been growing gradually for last 5 years in
accordance with long-lasting and promising effects. Hess
performed sleeve gastrectomy for the first time in 1988 as
part of a duodenal switch (DS) with biliopancreatic
diversion (BPD) [15]. Johnston et al. presented this method
in 1993 as an isolated technique, and in 1999 the first
laparoscopic sleeve gastrectomy was conducted as part of
BPD–DS [16, 17]. The procedure is now performed
laparoscopically and consists of total gastric resection of
the fundus and body from the greater curvature and creation
of long, tubular gastric conduit constructed along the lesser
curvature of the stomach. Weight loss and improvement in
parameters of metabolic syndrome are connected with the
resection of the stomach and with following neurohormonal
changes. Currently, LSG is recommended as an isolated,
definite, and efficient bariatric surgery providing effects not
only in morbid obesity treatment but also in improvement
of diabetes (DMT2) and metabolic syndrome (MS) [18–
20]. Due to the fact that SG is one of the youngest methods
of treating morbid obesity, there is some kind of a gap in
the world literature concerning the influence of this
bariatric procedure on parameters of metabolic syndrome
and co-morbidities of obesity. The aim of our research is to
determine changes in parameters of metabolic syndrome
(BMI, blood pressure, glucose concentration, HDL, trigly-
cerides) 1 year after the surgery in 130 obese patients who
underwent sleeve gastrectomy. The influence of LSG on
insulin, and total and LDL cholesterol concentration in
plasma of obese patients and the influence of reduction in
body mass on co-morbidities were also analyzed.
Materials and Methods
The material consists of 130 patients hospitalized in our
department from 2007 to 2010 who underwent laparoscopic
sleeve gastrectomy (LSG) in order to treat morbid obesity and
whohadmetbeforethesurgeryatleastthreecriterianecessary
for the diagnosis of metabolic syndrome according to the
International Diabetes Federation (visceral obesity BMI
>30 kg/m
2, hypertriglyceridemia ≥150 mg/dl, low HDL
cholesterol M<40 mg/dl W<50 mg/dl, hypertension RR≥
130/85 mmHg, fasting hyperglycemia ≥100 mg/dl, or earlier
recognized type 2 diabetes). In order to determine the
influence of LSG on the level of metabolic syndrome
reduction in obese patients in early postoperative period,
we limited the observation period (follow-up) to 1 year. In
the examined group, qualified for LSG were 72 women
(average age 48.73±9.5 years) and 58 men (average age
46.19±9.6 years). Average body mass in women was
139.2±21.8 kg and was slightly lower than in men—
149.4±24.28 kg. Preoperative BMI in both groups was
53.18±7.8 kg/m
2; among women it was 51.39±6.7 kg/m
2
and in men it was 55.06±8.3 kg/m
2. Waist circumference
was at an average level of 122.8±18.4 cm in women and
134.2±27.6 cm in men (Table 1).
Among the criteria we adopted, all examined patients
before the qualification for LSG had met at least three
criteria necessary for the diagnosis of metabolic syndrome
according to the International Diabetes Federation (IDF)
(100%). Seventy-four patients (56,92%) met four criteria
for MS and 32 patients (24.61%) met five criteria for the
diagnosis of metabolic syndrome (Fig. 1).
Among all available bariatric procedures, the choice of
LSG was dictated by the following indications: BMI >50
and three criteria for metabolic syndrome or BMI <50 and
four to five criteria for MS, age >40 or <40 but with three
co-morbidities. Laparoscopic sleeve gastrectomy has be-
come the method of choice for these patients according to
the criteria mentioned above. Patients qualified for surgical
treatment have been controlled for co-morbidities in order
to establish appropriate preoperative treatment. Before the
surgery, the majority of patients had suffered from sleep
apnea (61 patients, 46.92%); hypertension occurred in 59
patients (53.07%), type 2 diabetes in 41 patients (31.53%),
depressive disorders in 39 patients (30%), and chronic
obstructive pulmonary disease (COPD) in 38 patients
(29.23%); coronary artery disease was diagnosed in 21
patients (16.15%), cholelithiasis in 19 patients (14.61%),
and varicose veins in 17 patients (13.07%). The occurrence
of all co-morbidities observed in the examined group before
the surgery is presented in Table 4. Patients were consulted
preoperatively by an endocrinologist, diabetologist, and
psychologist, and women by a gynecologist. Biochemical
Table 1 Age, waist circumference, body mass, and BMI obese
patients in own material
Women Men
Age (years) 48.93±9.5 46.19±9.6
Waist circumference (cm) 122.8±18.4 134.2±27.6
Body mass (kg) 139.2±21.8 149.4±24.28
BMI (kg/m
2) 53.18±7.5 55.06±8.3
14 OBES SURG (2012) 22:13–22tests were performed: glucose, insulin, triglycerides, total
cholesterol, and HDL and LDL cholesterol. The results are
presented in Table 2.
Medical imaging was also performed (chest X-ray,
abdominal USG, and gastroscopy) in order to exclude
possible pathologies of the gastrointestinal tract. Echocar-
diography was conducted in patients with coronary artery
disease or in patients after heart attack. In patients with the
risk of occurrence of venous thromboembolism, Doppler
ultrasonography of lower limb veins was conducted. In
patients with COPD or in cases of suspected sleep apnea,
polysomnography or rhinomanometria was performed.
One panel of surgeons (one operator and two assistants)
performed all procedures laparoscopically. LSG began with
precise examination of the stomach and localization of
crow’s foot. Using a harmonical knife or LigaSure®,
gastrocolic omentum was cut next to the wall of the
stomach and in the middle of gastrocolic omentum vessels.
Cut-off line of the omentum reached upwards to the left
diaphragmatic branch and downwards approximately 4–
6 cm from the pylorus. The first charge separated greater
curvature towards the crow’s foot, and the following
charges separated the curvature along the body of the
stomach to the angle of His. Possible bleeding from the cut-
off line was preserved immediately with coagulation or by
hematostatic stitch. The stomach was reduced to the narrow
tube with a diameter of 35 F; tightness was checked by
methylene blue test. Finally, the drain near the cut-off line
was placed. The surgery lasted approximately 64 min.
Patients were discharged home in the second or third day
after the surgery and were under the control of a clinical
dietician and out-patient clinic. Generally, a low-calorie diet
was recommended. During the first 2 weeks, a low-sodium,
semi-liquid diet was advised with the continuance of low-
fat and low-carbohydrate diet.
All patients were examined 1, 3, and 6 months and
1 year after the surgery. Fasting 10–1 2hs i n c el a s t
meal, blood was taken for a clot tube and then
centrifuged until serum was obtained. Insulin, glucose,
total cholesterol, HDL cholesterol, LDL cholesterol, and
triglycerides were evaluated in order to control changes
in particular time points after the surgery. Rates of %
EWL, %EBL, and HOMA-IR, calculated according to
the following formula: HOMA   IR ¼ insulin mU=ml ½    f
glucose fasting ðÞ mmol=l ½  g 22:5,w e r ec o n s i d e r e dt ob e
accurate. Evaluation of %EWL and %EBL was prepared
based on data from 2007. Statistical analysis was prepared
using Statistics 6 software for Windows. Values of p <0.05
were found statistically significant.
Results
According to the analysis of obtained material, it is
possible to state that 1 month after LSG, a statistically
significant (p<0.01) decrease in BMI (45.70±7.8 kg/m
2)
was observed in comparison to preoperative period (53.18±
7.5 kg/m
2). Six-month and 1-year follow-up confirmed
further statistically significant (p<0.0001) decreases in BMI
(31.4±3.75 kg/m
2—1 year after the surgery). The greatest
decrease was observed between the third and sixth month
after the surgery (7.1 kg/m
2)( F i g .2).
During 1-year follow-up, the decrease of body mass
excess weight loss (EWL) and BMI excess body mass
index loss (EBL) was observed. One month after the LSG,
the percentage of weight loss was statistically significant
and was equal to 22.34±3.85%. One year after the surgery,
EWL reached 59.42±7.21%. The reduction in BMI was
gradually improving and in every time point remained
statistically significant. In the first month after surgical
treatment, a statistically significant (p<0.0001) decrease in
Table 2 Preoperative values of examined parameters
Insulin (μU/l) 44.8±25.82
Glucose (mg/dl) 149.9±58.54
Total cholesterol (mg/dl) 218.05±17.61
Triglycerides (mg/dl) 172.3±48.8
LDL cholesterol (mg/dl) 148.42±35.5
HDL cholesterol (mg/dl) 42.48±10.15
HOMA-IR 13.2±11.8
Fig. 1 The amount of patients
who met three, four, or five
criteria for the diagnosis of
metabolic syndrome
OBES SURG (2012) 22:13–22 15BMI was observed—24.52±5.19%. At 1-year follow-up,
EBL in examined group of patients reached the level of
61.03±6.50% (Figs. 3 and 4).
Changes in patients’ waist circumference after LSG have
also been analyzed, differentiating men from women. The
results remained statistically significant in every stage of
observation. After 1 year, waist circumference in women
decreased from 122.8±18.4 cm to 89±8.2 cm and in men
from 134.2±27.6 cm to 106±9.66 cm (Fig. 5).
During 1-year postoperative observation, statistically
significant changes in insulin concentration in plasma have
been observed in every stage of observation in comparison
to preoperative values (44.8±25.82 IU/l). Changes in
concentration of insulin are presented in Table 3. All results
of glucose concentration also appeared statistically signif-
icant with a tendency to decrease in comparison to
preoperative values (149.9±58.54 mg/dl). The greatest
reduction in concentration of glucose in serum was
observed (105.9±12.8 mg/dl) 1 month after the surgery;
however, the results were statistically significant in every
stage (p<0.05). Beneficial correlations between glucose,
insulin, and BMI reduction were observed. Our research
indicates that the value of HOMA-IR was statistically
significant in every stage of observation of patients after
Fig. 2 Postoperative changes in
BMI in 130 patients at 1-year
follow-up
Fig. 3 Percentage of weight
loss (%EWL) after LSG in 130
patients at 1-year follow-up
16 OBES SURG (2012) 22:13–22LSG. After 1 year, its value decreased from 13.20±11.8 to
3.02±1.98 (Table 3).
After the analysis of postoperative results in 130
patients after LSG, a beneficial effect of the surgery on
all components of the lipid profile was observed.
Considering total cholesterol concentration, we observed
a statistically significant decrease of its value only just
3 months after the surgery. In the first month, reduction
of cholesterol was statistically insignificant; however,
between the third and sixth month, the decrease has
stopped and remained on the same level. Further
decrease has been observed since the sixth month after
the surgery. During the examination of triglycerides
concentration, we stated a statistically significant de-
crease of its value after 1 month (125.7±24.6 mg/dl),
after 3 months (119.5±20.5 mg/dl), and after 1 year
(90.65±25.11 mg/dl) in comparison to the preoperative
value (172.3±48.8 mg/dl). Only a slight decrease in
Fig. 4 Percentage of BMI
decrease (%EBL) after LSG in
130 patients at 1-year follow-up
Fig. 5 Postoperative changes in
waist circumference in 130
patients at 1-year follow-up
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surgery (43.3±8.8 mg/dl) in comparison to the preoper-
ative value (42.48±10.15 mg/dl). Examination of HDL
cholesterol 1 month and 3 months after LSG showed a
slight decrease of its concentration in serum in compar-
ison to preoperative values. Taking into consideration
the concentration of triglycerides, the decrease has
stopped on the same level during the whole observation
period. The greatest decrease was observed 1 month
after the surgery (125.7±24,6 mg/dl) (Fig. 6).
Co-morbidities
Among 41 patients with type 2 diabetes, 22 demonstrated
complete recovery and in 19 patients a significant improve-
ment was observed. In 12 patients, it resulted in halving the
daily dose of insulin and seven patients turned insulin
therapy to oral hypoglycemic drugs. In 38 patients
(55.07%), a significant improvement of hypertension was
observed. According to surgical treatment, in 20 patients it
was possible to reduce application of antihypertensive
drugs from three to one. In 18 patients, three previously
applied medications were replaced by two due to normal-
ization in blood pressure. Bariatric procedures also allowed
to reduce drug doses for patients with COPD noticed
preoperatively (Table 4).
Among other co-morbidities cured after bariatric proce-
dure (LSG), the following have to be mentioned: sleep
apnea (improvement in 36.06% patients) and depressive
disorders (improvement in 17.94% patients). After bariatric
procedure, five of six patients with osteoarthritis were
qualified to hip endoprosthesis implantation, and three
patients were qualified to knee prosthesis implantation
which was not possible preoperatively but could surely
improve their quality of life.
In 11 patients, LSG and cholecystectomy were performed
simultaneously in order to cure cholelithiasis. Additional
improvement has been obtained in following co-morbidities:
ulceration and thrombophlebitis. It was a result of conserva-
tive treatment applied before the surgery which was also a
requirement during qualification for bariatric operation.
During 1-year follow-up, we observed severity of
symptoms in two co-morbidities: GERD and esophagitis.
The amount of patients with GERD symptoms after LSG
Table 3 Postoperative changes in insulin concentration, glucose level, and HOMA-IR
1 month p value 3 months p value 6 months p value 12 months p value
Insulin 20.1±15.4 <0.01 16.1±12.2 <0.01 15.2±8.4 <0.05 13.11±5.25 <0.05
Glucose 105.9±12.8 <0.05 101.55±10.1 <0.01 98.5±6.2 <0.05 91.76±6.8 <0.05
HOMA-IR 4.4±3.4 <0.001 4.02±3.2 <0.01 3.66±2.48 <0.01 3.02±1.98 <0.05
Fig. 6 Postoperative changes in
lipid profiles
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(12.3%) after LSG esophagitis was diagnosed while
preoperatively it was visible in 12 patients (9.23%)
(Table 5).
The reduction in frequency of occurrence of metabolic
syndrome in obese patients after LSG is presented in Fig. 3.
Statistical analysis of obtained results proved that 1 year
after sleeve gastrectomy the amount of patients with
possible metabolic syndrome (the occurrence of at least
three criteria of metabolic syndrome according to IDF)
decreased in 61 patients (53.08%) which is 46.92% of all
patients with metabolic syndrome after LSG. Six months
from the surgery, the amount of patients with five criteria of
metabolic syndrome decreased to about 75%. After 1 year,
none of the patients met five criteria of metabolic syndrome
(before the surgery it was 32 patients) (Fig. 7).
Discussion
Metabolic syndrome as a collection of correlating risk
factors of diabetes and cardiovascular diseases is recently
clinically and epidemiologically important because of
correlation with obesity and constantly increasing number
of cases. Its recognition increases five times the risk of
developing type 2 diabetes and two times the risk of
sclerosis, as well as their consequences—morbidity and
mortality as a result of cardiovascular complications [21].
Currently, there is a trend to pay particular attention to the
criteria of metabolic syndrome. In 2009, common consen-
sus was published stating that three criteria from five
Table 4 Improvement in
co-morbidities 1 year
after LSG
Co-morbidities Before surgical treatment Improvement after 1 year Recovery
Amount % Amount % Amount %
Hypertension 59 53.07 38 55.07
Sleep apnea 61 46.92 39 63.93 22 36.06
Type 2 diabetes 41 31.53 19 46.34 22 53.66
Depressive disorders 39 30.00 10 25.64 7 17.94
Chronic obstructive
pulmonary disease
38 29.23 25 65.79
Coronary artery disease 21 16.15 8 6.15
Cholelithiasis 19 14.61
Spinal disc herniation 19 14.61 19 100.00
Varicose veins 17 13.07 8 47.05
Peptic ulcer disease 11 8.46
Hemorrhoids 9 6.92 2 22.22
Crus ulcer 6 4.61 4 66.66
Hip osteoarthritis 6 4.61 5
Heart attack 6 4.61
Deep vein thrombosis 5 3.84
Knee arthritis 3 2.30 3
Fig. 7 The amount of patients with diagnosed metabolic syndrome
(met three, four, or five criteria MS according to IDF) 6 months or
1 year after LSG
Table 5 Influence of LSG on GERD and esophagitis symptoms
Before the surgery 1 year after LSG
n % n %
GERD 14 10.76% 18 13.84%
Esophagitis 12 9.23% 16 12.30%
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syndrome: abdominal obesity (Caucasian Europeans—
waist circumference=M >94 cm, W >80 cm); hyper-
triglyceridemia ≥150 mg/dl (1.7 mmol/l); low HDL
cholesterol concentration M <40 mg/dl (1.03 mmol/l),
W <50 mg/dl (1.29 mmol/l); hypertension RR ≥130/
85 mmHg; and fasting hyperglycemia ≥100 mg/dl
(5.6 mmol/l) or diagnosed earlier type 2 diabetes but
without obesity as a main criterion [22]. According to
different studies, the frequency of occurrence of metabolic
syndrome is high but differs depending on the examined
population and adapted criteria. According to data from
the Third National Health and Nutrition Examination
Survey, the occurrence of MS is determined by the criteria
of NCEP ATP III, and it is estimated at 34.5% of the
whole population—33.7% in men and 35% in women.
According to criteria of IDF, MS occurs in 39–40% of
m e na n d3 8 %o fw o m e n[ 8]. Undoubtedly, it is a result of
obesity epidemic observed all over the world in accor-
dance with proven correlation between metabolic syn-
drome and excessive body mass [23]. Accumulation of
visceral fat and insulin resistance are the main pathoge-
netic factors of MS [24]. Bariatric surgery, which is the
method of choice in treatment of morbid obesity, allowed
to normalize body mass, extended postoperative observa-
tions also effect favorably showed that other parameters of
metabolic syndrome and cures type 2 diabetes [25, 26].
LSG is respectively a new method among other bariatric
procedures. The method is undoubtedly effective since it
leads to body weight loss [27]. The results revealed after
observation period shorter than 1 year indicate that body
mass loss is more significant after LSG than after other
bariatric procedures [28–30] .A c c o r d i n gt ol o wp e r i o p e r -
ative risk even in patients with many co-morbidities, this
procedure was firstly recommended for super obese
patients (BMI >50 kg/m
2) with high perioperative risk or
as an introduction to laparoscopic Roux-en-Y gastric by-
pass [31]. Nowadays, it is recommended as a primary,
restrictive procedure leading to effective body mass loss
even in super obese patients [30]. It is highly recommen-
ded for patients with high perioperative risk connected with
co-morbidities due to its short operation time (80–120 min)
and minimal risk of complications. Previous observations
showed that all bariatric procedures lead to body weight loss
[19]. Body weight loss after LSG—as proven by 5-year
observations—is effective and satisfying for patients and
leads to improvement of quality of life. Our 1-year
observation revealed results similar to the results of other
authors [32].
Next to the favorable effects on body mass loss, LSG
effectively decreases insulin resistance in accordance with
improvement of glucose metabolism which results in
restoration of type 2 diabetes or in lowered requisition for
hypoglycemic drugs or insulin. Buchwald et al. in his meta-
analysis showed the remission of type 2 diabetes in 76,8%
of patients after bariatric procedure [19]. Silecchia et al.
presented the restoration of insulin-dependent diabetes in
76.9% of patients and improvement in 15.4% of obese
patients after LSG [33]. In another study, regression of
type 2 diabetes post-LSG was shown in 27% of patients
2 months after the surgery and respectively in 63% of
patients after 6 months [34]. Furthermore, it was observed
that patients with T2DM lasting <5 years have gained better
effects after surgical treatment. In our research, we have
also presented the regression of diabetes at 1-year follow-up
in 53.66% of patients who underwent LSG and improve-
ment in 43.34% of patients, which confirmed the effective-
ness of LSG in treatment of diabetes in obese patients with
metabolic syndrome. While the increasing amount of
studies confirms beneficial influence of bariatric procedures
on glucose metabolism and insulin resistance, studies
which recommend bariatric treatment for diabetes in
patients with BMI <30 kg/m
2 recently appeared. The
application of LSG also significantly decreases the
demand for antihypertensive drugs in accordance with
normalizing blood pressure. In our research, in 20 out of
38 patients who showed improvement after bariatric
surgery, one out of three antihypertensives was left and
respectively in 18 patients two out of three were left.
Generally, improvement regarding hypertension concerned
55.07% of patients.
Similarly to Assimakopoulos, we proved in our
research the total elimination of depressive disorders in
17.94% of patients while in 25.64% we observed a
significant improvement in mental state [35]. Our results
showed that bariatric operation had normalized body mass
in three patients (100%) with hip osteoarthritis and in five
patients (83.3%) with knee arthritis, and at the same time
allowed to qualify those patients to orthopedic surgery in
order to cure the co-morbidities mentioned. LSG led, in all
patients with recognized discopathy at 1-year follow-up,
to regression in pain, while six patients were qualified to
neurosurgical treatment. Analyzing the influence of LSG
on particular co-morbidities, we observed the increase in
GERD symptoms of about 3.08% and in esophagitis
symptoms of 3.07%. Brethauer et al. presented similar
results on the effect of LSG. It is probably a result of
chosen surgical technique which is changing the structure
of the stomach and motor activity of the upper gastroin-
testinal tract [36]. Explanation of this issue needs further
clinical examinations.
LSG undoubtedly improves lipid profile parameters;
however, some long-term studies present that this trend is
not always maintained, especially more than 2 years after
the surgery. Zhang et al. also indicate that low level of HDL
cholesterol and high triglycerides are the main risk factors
20 OBES SURG (2012) 22:13–22for cardiovascular diseases in obese patients [37]. In our
studies, 1 year after LSG, we obtained not only the decrease
of LDL cholesterol, triglycerides, and total cholesterol but
also the increase of HDL cholesterol; however, short-term
results (before the third month after surgery) were not
satisfying. Our results correlate with those published in
world literature. Obtained results indicate that bariatric
surgery may effectively influence dyslipidemia connected
with obesity.
According to relatively short time of observation, there
is a lack of research comparing the influence of other
bariatric procedures (including sleeve gastrectomy) on
overall range of parameters of metabolic syndrome. When
sleeve gastrectomy was not taken into consideration,
modified biliopancreatic diversion or gastric bypass was
considered to be the best method to reduce parameters of
metabolic syndrome. It elevates the value of our research
which allows us to see more completely the influence of the
youngest surgical techniques on parameters of metabolic
syndrome.
Conclusions
According to efficiency in body mass loss presented by
%EWL and %EBL, laparoscopic sleeve gastrectomy is
gaining approval as a method of obesity and metabolic
syndrome treatment, although it is a relatively new
procedure. It has been confirmed in our material. Basing
on the literature and our own material, it can be stated
that LSG is rather an easy procedure, the time of
performance and hospitalization are shorter which
entails lower costs, and it is more effective for patients
with metabolic syndrome and for super obese patients
with co-morbidities. Sleeve gastrectomy normalizes all
parameters of metabolic syndrome and significantly
decreases the percentage of obese patients with meta-
bolic syndrome which is now the main cause of
cardiovascular complications. It also brings beneficial
effects for patients with osteoarticular disease, depres-
sive disorders, or sleep apnea. Only in case of GERD
and esophagitis LSG intensifies symptoms which should
be the subject for further examination.
Bariatric surgery is currently evolving and searching for
new methods to not only reduce body mass but also to
make the treatment of metabolic syndrome or type 2
diabetes efficient. In the future, it will allow the adoption
of proper procedure to particular therapeutic needs in
patients with morbid obesity.
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